This company develops oral vaccines targeting gastrointestinal diseases like rotavirus and norovirus, primarily for children and adults. Their platform allows for rapid adaptation of vaccine antigens to match circulating strains of pathogens, enabling more effective protection against evolving GI illnesses.
Funding
Funding not disclosed
Founders
Product
Problem
Gastrointestinal (GI) illnesses, such as those caused by rotavirus and norovirus, pose a significant health burden, particularly for children and older adults. Current preventative measures are often limited in scope and effectiveness against the rapidly evolving strains of these viruses. This results in frequent outbreaks and substantial healthcare and economic costs globally.
Solution
GIVAX is developing a novel class of GI vaccines using a rotavirus-based vector platform to address the limitations of existing vaccines. By manipulating the rotavirus genome, GIVAX can express vaccine antigens targeting multiple GI pathogens, including rotavirus and norovirus. This platform enables rapid adaptation of vaccine antigens to match circulating strains, offering a more flexible and effective approach to GI disease prevention. The oral vaccine aims to induce mucosal immunity in the GI tract, which is crucial for protecting the pediatric population. GIVAX's approach has the potential to significantly reduce the global burden of GI illnesses.
Target Audience
The primary target audiences are children and adults at risk of contracting rotavirus, norovirus, and other gastrointestinal diseases, as well as public health organizations seeking to reduce the incidence and severity of GI outbreaks.
Features
- Novel oral replicating rotavirus vector for safe and effective GI vaccines
- Pediatric vector based on licensed vaccines with an established safety profile
- Adult vector has demonstrated clinical safety
- Ability to induce de-novo mucosal immunity in the GI tract
- Flexible platform allows for easy updates to antigen composition to match circulating strains without changing manufacturing processes
- Dual rotavirus/norovirus vaccine for pediatrics
- Norovirus vaccine for adults
- Potential for vaccines targeting other gastrointestinal pathogens, such as _Clostridioides difficile (C. Diff)_